Circulating insulin-like growth factor I in relation to melanoma risk in the European Prospective Investigation into Cancer and Nutrition

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

DOI

    Kathryn E Bradbury, National Institute for Health Innovation, School of Population Health, The University of Auckland, Auckland, New Zealand., New ZealandPaul N Appleby, Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK., StorbritannienSarah J Tipper, Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK., StorbritannienRuth C Travis, Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK., StorbritannienNaomi E Allen, Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, UK., StorbritannienMarina Kvaskoff, Institut Gustave Roussy, Villejuif, France., Frankrig
  • Kim Overvad
  • Anne Tjønneland, Danish Cancer Society Research Center, Danish Cancer Society, Copenhagen, Denmark., DanmarkJytte Halkjaer, Danish Cancer Society Research Center, Danish Cancer Society, Copenhagen, Denmark., DanmarkIris Cevenka, Institut Gustave Roussy, Villejuif, France., FrankrigYahya Mahamat-Saleh, Institut Gustave Roussy, Villejuif, France., FrankrigFabrice Bonnet, CHU Rennes, EA 1254 Microbiologie Risques infectieux, Université de Rennes 1, Rennes, France., FrankrigRudolf Kaaks, Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany., TysklandRenée Turzanski Fortner, Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany., TysklandHeiner Boeing, Department of Epidemiology, German Institute of Human Nutrition (DIfE) 14558 Potsdam-Rehbrücke, Nuthetal, Germany., TysklandAntonia Trichopoulou, Hellenic Health Foundation, Athens, Greece, GrækenlandCarlo La Vecchia, Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milan, Italy., ItalienAlexander J Stratigos, 1st Department of Dermatology - Venereology, National and Kapodistrian University of Athens School of Medicine, Andreas Sygros Hospital, Athens, Greece., GrækenlandDomenico Palli, Cancer Risk Factors and Life-Style Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network, ISPRO, Florence, Italy., ItalienSara Grioni, Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milano, Italy., ItalienGiuseppe Matullo, Italian Institute for Genomic Medicine (IIGM/fka HuGeF), Torino, Italy., ItalienSalvatore Panico, Dipartmento di Medicina Clinica E Chirurgia, Federico II University, Naples, Italy., ItalienRosario Tumino, Cancer Registry and Histopathology Department, "Civic M.P. Arezzo" Hospital, ASP, Ragusa, Italy., ItalienPetra H Peeters, Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, 3584 Utrecht, The Netherlands., HollandBas Bueno-de-Mesquita, Department for Determinants of Chronic Diseases (DCD), National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands., HollandReza Ghiasvand, Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, Institute of Basic Medical Sciences, University of Oslo, Norway., NorgeMarit B Veierød, Department of Community Medicine, Faculty of Health Sciences, University of Tromsø - The Arctic University of Norway, Tromsø, Norway., NorgeElisabete Weiderpass, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden, SverigeCatalina Bonet, Unit of Nutrition and Cancer. Cancer Epidemiology Research Program. Catalan Institute of Oncology-IDIBELL. L'Hospitalet de Llobregat, Barcelona, Spain., SpanienElena Molina, CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain., SpanienJosé María Huerta, Department of Epidemiology, Regional Health Council, IMIB-Arrixaca, Murcia, Spain., SpanienNerea Larrañaga, Public Health Division of Gipuzkoa-BIODONOSTIA, Basque Regional Health Department, Donostia, SpanienAurelio Barricarte, Navarre Public Health Institute, Pamplona, Navarra Institute for Health Research (IdiSNA), Pamplona, Spain., SpanienSusana Merino, Public Health Directorate, Asturias, Spain., SpanienKarolin Isaksson, Breast and Melanoma Unit, Lund University, Skåne University Hospital, Department of Clinical Sciences, Surgery, Lund, Sweden., SverigeTanja Stocks, Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden., SverigeIngrid Ljuslinder, Department of Radiation Sciences, Oncology, Norrlands University Hospital, Umeå, Sweden., SverigeOskar Hemmingsson, Department of Surgical and perioperative Sciences/Surgery, Umeå University, Umeå, Sweden., SverigeNick Wareham, MRC Epidemiology Unit, University of Cambridge, Cambridge, UK., StorbritannienKay-Tee Khaw, Department of Public Health and Primary Care, University of Cambridge., StorbritannienMarc J Gunter, Section of Nutrition and Metabolism, International Agency for Research on Cancer, World Health Organization, Lyon, France., FrankrigSabina Rinaldi, Section of Nutrition and Metabolism, International Agency for Research on Cancer, World Health Organization, Lyon, France., FrankrigKonstantinos K Tsilidis, Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece, GrækenlandDagfinn Aune, Department of Clinical Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital, Institute of Clinical Medicine, Oslo University, Oslo, Norway., NorgeElio Riboli, 17 Department of Epidemiology and Biostatistics, School of Public Health, Faculty of Medicine, Imperial College London, London, UK., StorbritannienTimothy J Key, Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK., Storbritannien

Insulin-like growth factor (IGF-I) regulates cell proliferation and apoptosis, and is thought to play a role in tumour development. Previous prospective studies have shown that higher circulating concentrations of IGF-I are associated with a higher risk of cancers at specific sites, including breast and prostate. No prospective study has examined the association between circulating IGF-I concentrations and melanoma risk. A nested case-control study of 1221 melanoma cases and 1221 controls was performed in the European Prospective Investigation into Cancer and Nutrition cohort, a prospective cohort of 520,000 participants recruited from 10 European countries. Conditional logistic regression was used to estimate odds ratios (ORs) for incident melanoma in relation to circulating IGF-I concentrations, measured by immunoassay. Analyses were conditioned on the matching factors and further adjusted for age at blood collection, education, height, BMI, smoking status, alcohol intake, marital status, physical activity, and in women only, use of menopausal hormone therapy. There was no significant association between circulating IGF-I concentration and melanoma risk (OR for highest vs lowest fifth=0.93 (95% confidence interval (CI): 0.71 to 1.22)). There was no significant heterogeneity in the association between IGF-I concentrations and melanoma risk when subdivided by sex, age at blood collection, BMI, height, age at diagnosis, time between blood collection and diagnosis, or by anatomical site or histological subtype of the tumour (Pheterogeneity≥0.078). We found no evidence for an association between circulating concentrations of IGF-I measured in adulthood and the risk of melanoma. This article is protected by copyright. All rights reserved.

OriginalsprogEngelsk
TidsskriftInternational Journal of Cancer
Vol/bind144
Tidsskriftsnummer5
Sider (fra-til)957-966
Antal sider10
ISSN0020-7136
DOI
StatusUdgivet - 1 mar. 2019

Se relationer på Aarhus Universitet Citationsformater

ID: 132530466